On the basis of the above results showing that inactivation of the LKB1–AMPK axis contributes to EGFR TKI resistance in EGFRWT NSCLC, we sought to explore potential approaches to overcome resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.